Darrell S. Rigel, MD, MS, FAAD, answers the question of what is up coming in the world of dermatology in the way of precision medicine.
Mindera Health and a national health insurance company launched a pilot program to improve moderate-to-severe psoriasis management with precision medicine.
Recent data tracks the first realization of precision medicine for patients with psoriasis.
Click here to answer this weeks poll.
In 2023 as many as 11 biosimilars to Humira are headed for the US market.
A phase 3 study conducted by Amgen found that the company’s ustekinumab biosimilar was as safe and efficacious as the reference product (Stelara) in patients with moderate to severe plaque psoriasis.
Experts explored out-of-the-box solutions for treating challenging skin and hair disorders at the American Academy of Dermatology (AAD)’s 2022 Annual Meeting held March 25 to 29, 2022, in Boston, Massachusetts.
If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.
Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.
Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).